host number meet ilmn ceo earli august meet serv
platform discuss recent posit trend outlin outlook
key driver sustain momentum seem posit tip point
base meet review quarterli materi revis model
increas price target
summari observ
mani comment made meet fortifi convict
outlook sequenc consum revenu growth balanc forecast
period elast seem aliv well room innov novaseq
platform mani excit growth area get go
biopharma consum health system sequenc nipt averag risk patient popgen
mid-teen margin-expand consum revenu growth drive financi result
exceed street expect believ success move
narrative/thesi focu applications/consum use rather prior boom/
bust instrument placement cycl like support sustain period stock
appreci current level
concurr report base meet dilig updat
model increas price target base dcf analysi
cadenc hiseq transit consist manag expect
manag indic lab hiseq plan replac
fleet novaseq other like eventu transit nextseq lower
throughput higher cost/bas consist check manag indic
replac take time content dynam note
pace allow prolong multi-year replac cycl
recent hiseq non-x instrument replac novaseq per quarter
increas manag indic could earli sign
core lab custom increasingli shift novaseq
manag note major genom center purchas least one
novaseq transit entir hiseq fleet
manag will share expect replac ratio note
expect hiseq xs replac hiseq non-x replac
aggreg forecast non-x hiseq retir
put perspect instal base hiseq xs
head novaseq launch
continu page
pleas see page report import disclosur
well posit maintain leadership expand high-end genet
tool research market drive robust growth nipt market increasingli displac
exist diagnost establish reimburs act arm dealer
elimin barrier sequenc becom increasingli use oncolog adjac
market believ factor continu translat robust doubl digit revenu
earn growth justifi premium valuat
nextseq key growth driver
continu evolv favor
novaseq unabl catalyz
nextseq placement continu increas
new instruments/kit surpris
strength nextseq placement
sourc revenu
expand use sequenc increas
becom much favor
concern build oper leverag
slow materi
hiseq bigger expect headwind
leader genet tool segment tool diagnost market
segment compani broad portfolio system consum analysi tool
design simplifi genet analysi address rang genom complex price
point throughput enabl research select best solut scientif
challeng market leader next gener sequenc increasingli focus
reproduct health includ nipt act arm dealer emerg oncolog
one thing want note go back lab survey link earlier
year subsequ develop continu believ base survey
find replac ratio like exceed novaseq placement
forecast replac forecast correct
manag note custom move hiseq novaseq spent
manag expect sizeabl major hiseq custom
ad least one novaseq system increas overal spend consum
spite lower cost/data new sampl access deeper broader sequenc
key driver may earli call trend clearli encourag
go back survey math time base result
balanc novaseq tailwind sampl sequenc via broader
sequenc sampl wg deeper sequenc sampl headwind
lower price/data led us conclud novaseq placement could
drive least store sale growth per site hiseq swap out could
actual lead linear increas revenu per novaseq
exclud stock activ china attribut trade war uncertainti
estim novaseq gener averag annual consum
revenu manag made clear see reason believ peak
although longer term unknown long term instal base mix higher vs lower
throughput custom near term note manag indic could
stock activ china
novaseq afford opportun better segment applic custom
group ultim architectur allow allow custom
gener human genom compani made clear earli
curv come optim almost everi aspect novaseq architectur
clearli old tam estim date small
outlin total address market compon
includ core life scienc oncolog reproduct health
notabl omiss includ limit
rugd clinic applic cdx/drug develop liquid biopsi solid
tumor averag risk nipt popul studi china manag
acknowledg observ indic provid date
under-repres true opportun compani today
track popul program could start acceler activ
next sever quarter said one program genom england current
activ drive notabl revenu although note va million veteran program
gener revenu like chang
see posit indic broadli note specif allofu like
go initi pilot microarray sequenc later year end major french
popgen program expect commenc uk biobank project gain
momentum manag clear ton activ potenti
popul studi expect major revenu contributor
geising health leader pioneer broader use sequenc patient
notabl announc plan roll clinic exom sequenc patient
summer initi pilot intend return limit number
medic action result patient system also trust partner
biopharmaceut compani report system plan sequenc
patient come year addit manag indic geising
success catalyz system initi plan follow suit
encourag recent develop acog could lead broader use
reimburs non-invas pre-nat test average-risk popul bigger
high-risk popul clear support guidelin would help
develop posit complet necessari average-risk market
longer term could broaden sale nipt kit geographi
respons question emerg competit indic believ
content qualiti win
biopharma still account total sale manag believ much
bigger time compani see great exampl biopharma use genom
inform across mani applic includ patient recruit cohort delin
cdx develop expect revenu scale target therapi come
market note tmb test could drive test excit new
segment market
break-out year direct-to-consum test consum opt
genotyp prior year track
consum genom compani includ china yet number dtc compani
meaning contributor revenu less note microarray
consum revenu driven ag/bio although consum grow rapidli
manag note stock activ occur could also occur
like would quit meaning regardless even normal
stock china growth remain strong bulk order growth exceed
manag note order growth set new record exclud bulk order
note subsequ meet miseqdx approv china
posit develop albeit one manag indic anticip
materi revenu driver import next step get content
platform burn rock tumor mulit-gen kit recent approv cfda
make follow chang subsequ meet late-august review
materi
biggest chang model high end sequenc consum
revenu growth per year start follow growth
base growth driver list believ could prove conserv
survey work earlier year suggest could meaning upsid
also note estim captur uncertainti associ pace
notabl ep estim remain consensu even increas project
oper spend year
driven chang follow assumpt
 swap out
hiseq swap out
chang
chang
slightli higher run rate exclud bulk order
base momentum trend toward use swap
modest increas use placement reflect lower end hiseq swap out
increas price target base dcf translat
ep estim robust multipl note upsid dcf
support price target clearli multipl captur potenti upsid
arguabl fulli
compani report thomson eikon cowen compani
mm except per share guidancenet revenu guidanc y/i flat slightli q/qreport expect slightli reiter margin modestli q/q gener oper expect slightli lower sale similar slightli q/q non-oper interest year includ helix benefit net loss attribut nci add earn per ep helix dilut share expect share count share gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit greater-than-expect reduct academ
govern research fund competit commerci avail potenti
disrupt technolog price pressur caus competit increas demand
lower-pr instrument run-tim cost neg regulatori dynam
